How Precisely Can Prostate Cancer Be Managed?

키워드

참고문헌 (90)

1. Siegel RL, "Cancer statistics, 2016", CA Cancer J Clin, 66, pp.7~30 (2016)
2. Moyer VA, "Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement", Ann Intern Med, 157, pp.120~134 (2012)
3. Andriole GL, "Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial:mortality results after 13 years of follow-up", J Natl Cancer Inst, 104, pp.125~132 (2012)
4. Lavallée LT, "Reducing the harm of prostate cancer screening: repeated prostate-specific antigen testing", Mayo Clin Proc, 91, pp.17~22 (2016)
5. Lilja H, "Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin", Clin Chem, 37, pp.1618~1625 (1991)
6. Catalona WJ, "Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial", JAMA, 279, pp.1542~1547 (1998)
7. Roddam AW, "Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng", ml: systematic review and meta-analysis, 2005, pp.48, 386~399
8. Lee R, "A meta-analysis of the performance characteristics of the free prostate-specific antigen test", Urology, 67, pp.762~768 (2006)
9. Catalona WJ, "Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging", Urology, 56, pp.255~260 (2000)
10. Partin AW, "Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer", Prostate Cancer Prostatic Dis, 1, pp.197~203 (1998)
11. pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng, "ml prostate specific antigen range", J Urol, 185, pp.1650~1655 (2011)
12. proenzyme prostate specific antigen for prostate cancer detection:a national cancer institute early detection research network validation study, "J Urol", 2008, 539~543
13. proprostate-specific antigen-based prostate health index for detection of prostate cancer, "Clin Chem", 2013, 280~288
14. proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis, "Clin Chem Lab Med", 2013, 729~739
15. Bruzzese D, "Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with “gray” prostatespecific antigen levels at first biopsy: systematic review and metaanalysis", Transl Res, 164, pp.444~451 (2014)
16. Abrate A, "Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study", BJU Int, 115, pp.537~545 (2015)
17. proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng, "ml: a multicentric European study", Eur Urol, 63, pp.986~994 (2013)
18. de la Calle C, "Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men", J Urol, 194, pp.65~72 (2015)
19. Vickers AJ, "A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening", Cancer Epidemiol Biomarkers Prev, 20, pp.255~261 (2011)
20. Parekh DJ, "A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer", Eur Urol, 68, pp.464~470 (2015)
21. Bryant RJ, "Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study", J Natl Cancer Inst, 107(7), pp.djv095~ (2015)
22. Stattin P, "Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study", Eur Urol, 68, pp.207~213 (2015)
23. Hessels D, "DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer", Eur Urol, 44, pp.8~15 (2003)
24. de Kok JB, "Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors", Cancer Res, 62, pp.2695~2698 (2002)
25. Bussemakers MJ, "DD3: a new prostate-specific gene, highly overexpressed in prostate cancer", Cancer Res, 59, pp.5975~5979 (1999)
26. Groskopf J, "APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer", Clin Chem, 52, pp.1089~1095 (2006)
27. Auprich M, "Contemporary role of prostate cancer antigen 3 in the management of prostate cancer", Eur Urol, 60, pp.1045~1054 (2011)
28. Aubin SM, "PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial", J Urol, 184, pp.1947~1952 (2010)
29. Gittelman MC, "PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study", J Urol, 190, pp.64~69 (2013)
30. Wei JT, "Can urinary PCA3 supplement PSA in the early detection of prostate cancer?", J Clin Oncol, 32, pp.4066~4072 (2014)
31. Roobol MJ, "Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test", Eur Urol, 58, pp.475~481 (2010)
32. Bradley LA, "Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer", J Urol, 190, pp.389~398 (2013)
33. Sreekumar A, "Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression", Nature, 457, pp.910~914 (2009)
34. Khan AP, "The role of sarcosine metabolism in prostate cancer progression", Neoplasia, 15, pp.491~501 (2013)
35. Wiktor D. Sroka, "Determination of amino acids in urine of patients with prostate cancer and benign prostate growth", European Journal of Cancer Prevention, pp.1~ (2016), Ovid Technologies (Wolters Kluwer Health)[DOI]
36. Tomlins SA, "Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer", Science, 310, pp.644~648 (2005)
37. Laxman B, "Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer", Neoplasia, 8, pp.885~888 (2006)
38. Laxman B, "A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer", Cancer Res, 68, pp.645~649 (2008)
39. Hessels D, "Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer", Clin Cancer Res, 13, pp.5103~5108 (2007)
40. Tomlins SA, "Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA", Sci Transl Med, 3, pp.94ra72~ (2011)
41. Pinsky PF, "Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial", BJU Int, 99, pp.775~779 (2007)
42. Rastinehad AR, "Improving detection of clinically significant prostate cancer: magnetic resonance imaging", transrectal ultrasound fusion guided prostate biopsy, 2014, pp.191, 1749~1754
43. Mendhiratta N, "Magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in a consecutive cohort of men with no previous biopsy: reduction of over detection through improved risk stratification", J Urol, 194, pp.1601~1606 (2015)
44. Meng X, "Relationship between prebiopsy multiparametric magnetic resonance imaging (MRI), biopsy indication, and MRI-ultrasound fusion-targeted prostate biopsy outcomes", Eur Urol, 69, pp.512~517 (2016)
45. Stewart GD, "Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study", J Urol, 189, pp.1110~1116 (2013)
46. Partin AW, "Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies", J Urol, 192, pp.1081~1087 (2014)
47. Truong M, "Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer", Cancer, 119, pp.3992~4002 (2013)
48. Epstein JI, "Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy:incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades", Eur Urol, 61, pp.1019~1024 (2012)
49. Pinthus JH, "Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome", J Urol, 176, pp.979~984 (2006)
50. Bill-Axelson A, "Radical prostatectomy or watchful waiting in early prostate cancer", N Engl J Med, 370, pp.932~942 (2014)
51. Bolla M, "Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin", N Engl J Med, 337, pp.295~300 (1997)
52. Knezevic D, "Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies", BMC Genomics, 14, pp.690~ (2013)
53. Klein EA, "A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling", Eur Urol, 66, pp.550~560 (2014)
54. Cullen J, "A Biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer", Eur Urol, 68, pp.123~131 (2015)
55. Cuzick J, "Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort", Br J Cancer, 106, pp.1095~1099 (2012)
56. Freedland SJ, "Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy", Int J Radiat Oncol Biol Phys, 86, pp.848~853 (2013)
57. Cooperberg MR, "Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort", J Clin Oncol, 31, pp.1428~1434 (2013)
58. Cuzick J, "Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort", Br J Cancer, 113, pp.382~389 (2015)
59. Knudsen BS, "Application of a clinical whole-transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens", J Mol Diagn, 18, pp.395~406 (2016)
60. Lee HJ, "Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis.", Res Rep Urol, 8, pp.77~84 (2016)
61. Klein EA, "Decipher genomic classifier measured on prostate biopsy predicts metastasis risk", Urology, 90, pp.148~152 (2016)
62. Blume-Jensen P, "Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer", Clin Cancer Res, 21, pp.2591~2600 (2015)
63. Shipitsin M, "Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error", Br J Cancer, 111, pp.1201~1212 (2014)
64. Trock BJ, "Adjuvant radiation following radical prostatectomy: what are the known unknowns?", Eur Urol, 66, pp.251~252 (2014)
65. Ross AE, "Utility of risk models in decision making after radical prostatectomy:lessons from a natural history cohort of intermediateand high-risk men", Eur Urol, 69, pp.496~504 (2016)
66. Maurice MJ, "Low use of immediate and delayed postoperative radiation for prostate cancer with adverse pathological features", J Urol, 194, pp.972~976 (2015)
67. Kalbasi A, "Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features", Cancer, 120, pp.3089~3096 (2014)
68. Thompson IM, "Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival:long-term follow-up of a randomized clinical trial", J Urol, 181, pp.956~962 (2009)
69. Wiegel T, "Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen:ARO 96-02", AUO AP 09, J Clin Oncol, pp.2009, 27[DOI]
70. Bolla M, "Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)", Lancet, 380, pp.2018~2027 (2012)
71. Abdollah F, "Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis", Eur Urol, 63, pp.998~1008 (2013)
72. Erho N, "Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy", PLoS One, 8, pp.e66855~ (2013)
73. Karnes RJ, "Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population", J Urol, 190, pp.2047~2053 (2013)
74. Den RB, "Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy", Int J Radiat Oncol Biol Phys, 89, pp.1038~1046 (2014)
75. Klein EA, "A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy", Eur Urol, 67, pp.778~786 (2015)
76. Badani K, "Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group", Oncotarget, 4, pp.600~609 (2013)
77. Michalopoulos SN, "Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study", Curr Med Res Opin, 30, pp.1547~1556 (2014)
78. Badani KK, "Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery", BJU Int, 115, pp.419~429 (2015)
79. Nguyen PL, "Impact of a genomic classifier of metastatic risk on postprostatectomy treatment recommendations by radiation oncologists and urologists", Urology, 86, pp.35~40 (2015)
80. Feldman BJ, "development of androgen-independent prostate cancer", Nat Rev Cancer, 1, pp.34~45 (2001)
81. de Bono JS, "Abiraterone and increased survival in metastatic prostate cancer", N Engl J Med, 364, pp.1995~2005 (2011)
82. Scher HI, "Increased survival with enzalutamide in prostate cancer after chemotherapy", N Engl J Med, 367, pp.1187~1197 (2012)
83. Tannock IF, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer", N Engl J Med, 351, pp.1502~1512 (2004)
84. de Bono JS, "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial", Lancet, 376, pp.1147~1154 (2010)
85. Kantoff PW, "Sipuleucel-T immunotherapy for castration-resistant prostate cancer", N Engl J Med, 363, pp.411~422 (2010)
86. Parker C, "Alpha emitter radium-223 and survival in metastatic prostate cancer", N Engl J Med, 369, pp.213~223 (2013)
87. Li Y, "Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines", Cancer Res, 73, pp.483~489 (2013)
88. Mostaghel EA, "Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants", Clin Cancer Res, 17, pp.5913~5925 (2011)
89. Antonarakis ES, "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer", N Engl J Med, 371, pp.1028~1038 (2014)
90. Antonarakis ES, "Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer", JAMA Oncol, 1, pp.582~591 (2015)

관련 논문AI추천